Elsevier

Clinical Lung Cancer

Volume 5, Issue 2, September 2003, Pages 86-89
Clinical Lung Cancer

Research in Brief
Benefit of Active Treatment in Non–Small-Cell Lung Cancer in Elderly Patients and Patients with Poor Performance Status

https://doi.org/10.1016/S1525-7304(11)70325-4Get rights and content

First page preview

First page preview
Click to open first page preview

Cited by (4)

  • Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer

    2009, Lung Cancer
    Citation Excerpt :

    As a consequence, frequently in clinical practice an adequate dose intensity (DI) is difficult to be delivered. Since in NSCLC, chemotherapy DI has been related to treatment outcome [6–8], we performed a retrospective analysis on elderly patients treated at our Institution with chemotherapy for advanced NSCLC with the aim of assessing delivered DI and relationship to clinical outcome. This is a retrospective analysis performed on elderly patients with advanced NSCLC treated with chemotherapy at our Institution from January 1998 to June 2007.

  • Chemotherapy in the Older Patient with Operable Non-Small Cell Lung Cancer: Neoadjuvant and Adjuvant Regimens

    2009, Thoracic Surgery Clinics
    Citation Excerpt :

    Additionally, there was no interaction between age and chemotherapy effect, but there was a beneficial interaction between better performance status and treatment effect.5 When considering cisplatin-based adjuvant chemotherapy, poor ECOG performance status (PS 2 or worse) may be a relative contraindication for prescription of adjuvant therapy.78,79 This interaction is particularly pertinent to older patients with an increased frequency and severity of comorbid illnesses and greater vulnerability to physiologic stress.80

View full text